GRCE
Grace Therapeutics, Inc.
Key Financials
Revenue
$100.0M
N/A
Operating Income
$-11077000
↑ 33.6%
Total Liabilities
$2.8M
↓ 48.8%
Total Assets
$66.7M
↓ 7.4%
Shareholders' Equity
$63.9M
↓ 4.1%
EPS (Diluted)
$-0.47
↑ 40.5%
Net Income
$-7793000
↑ 18.6%
Cash & Equivalents
$17.0M
↓ 23.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/1/2026 | View on SEC |
| 4/A | 10/1/2026 | View on SEC |
| 4 | 9/23/2026 | View on SEC |
| 4 | 9/21/2026 | View on SEC |
| 4 | 9/21/2026 | View on SEC |
| 4 | 9/21/2026 | View on SEC |
| 4 | 9/21/2026 | View on SEC |
| 8-K | 9/18/2026 | View on SEC |
| 4 | 9/10/2026 | View on SEC |
| 4 | 9/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GRCE |
| Company Name | Grace Therapeutics, Inc. |
| CIK | 1444192 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | 609-322-1602 |